HS
HeartSciences Inc.
HSCS · NASDAQ
$4.68 -10.86% (-$0.57)
1M +69.57%
Market Cap $10.1M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.93
37.4% downside
Current Price
$4.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HSCS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
37 /100
Fair P/S 4.81x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 32.86%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 59.06%
Net margin 151,227.00%
Op. margin 140,107.00%
Quality
0 /100
Poor ROIC 149.42%
ROA 85.08%
Asset turnover 0.00x
Debt
0 /100
High Current ratio 0.14x
Int. coverage 0.03x
Debt/Equity N/A
Stability
2 /100
Unstable Beta 1.86x
Rev. volatility 191.53%
EPS volatility 2,569.73%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HSCS
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Andrew Simpson
Employees
14
Headquarters
Southlake
Upcoming events
21 DEC
Earnings
Upcoming earnings report